Search Results

Your search for Mirat Shah, MD, Atiqur Rahman, PhD, Marc R. Theoret, MD, and Richard Pazdur, MD,Mirat Shah, MD, Atiqur Rahman, PhD, Marc R. Theoret, MD, and Richard Pazdur, MD matches 2 pages

Showing 1 - 2

By Mirat Shah, MD, Atiqur Rahman, PhD, Marc R. Theoret, MD, and Richard Pazdur, MD / May 10, 2022

How to Get the Dose Right

OCE Insights is an occasional column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Mirat Shah, MD, of the Office of Oncologic Diseases, Center for Drug Evaluation and Research, FDA; Atiqur...

issues in oncology

By Matthew Stenger / October 2021

FDA Perspective on Drug-Dosing in Oncology: From ‘More Is Better’ to ‘Less Can Be More’

In a perspective article published in The New England Journal of Medicine entitled “The Drug-Dosing Conundrum in Oncology—When Less Is More,” four authors from the U.S. Food and Drug Administration (FDA) argue for the need to jettison the “more is better” paradigm in dose selection for oncology...

Nov

Today In Oncology

Search Results

Your search for Mirat Shah, MD, Atiqur Rahman, PhD, Marc R. Theoret, MD, and Richard Pazdur, MD,Mirat Shah, MD, Atiqur Rahman, PhD, Marc R. Theoret, MD, and Richard Pazdur, MD matches 2 pages

How to Get the Dose Right

FDA Perspective on Drug-Dosing in Oncology: From ‘More Is Better’ to ‘Less Can Be More’

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC